Please assess the completion status of the following clinical trial:

Trial Title: Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able to give written informed consent~* Meet validated clinical criteria for Alzheimer's disease, mixed dementia or MCI~* Age range greater than or equal to 60 years~* Stable general medical condition as assessed by the investigator~* Seizures which are partial in onset (with or without secondary generalization)~* Subjects with 4 or fewer seizures per month~* MMSE score of less than 28 at baseline~* Patients who are currently being treated with anticonvulsants or those with new onset seizures.~Exclusion Criteria:~* Patients with other clinically significant organic or neurological diseases. Patients considered medically unstable~* Patients in end stage renal disease requiring hemodialysis~* Patients with a known hypersensitivity to Levetiracetam~* Patients with primary generalized epilepsy~* Patients with brain tumors or other significant CNS abnormalities that are the primary cause of the seizures~* Patients with a history of status epilepticus~* Patients with severe psychiatric diagnoses or severe behavioral problems~* Dementia patients lacking a caregiver.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Levetiracetam (Type: EXPERIMENTAL): Levetiracetam was titrated over 4 weeks, with initial dosing of 250 mg bis in die (BID). Dosing was flexible and was based on the prescribing physician's discretion.

Based on this trial design, predict the completion outcome and termination type (if applicable).